Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19361301.
- Also identified by DOI 10.1086/598327.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Medical subject headings
- Antifungal Agents
- Azoles
- Drug Interactions